LeonaBio

01/09/2026

Today marks an important milestone for our company.
Athira Pharma is now LeonaBio, Inc., reflecting a transformative new chapter following our acquisition of rights to lasofoxifene, a Phase 3 program in metastatic breast cancer. Along with our new name, our Nasdaq ticker will change to LONA, effective January 12, 2026.
We remain dedicated to advancing innovative therapies for patients with serious diseases and high unmet medical need.
Read the full announcement: https://investors.athira.com/static-files/5a0c261e-d22b-4af9-87c7-bc15bda7315b

01/09/2026

Today marks an important milestone for our company.
Athira Pharma is now LeonaBio, Inc., reflecting a transformative new chapter following our acquisition of rights to lasofoxifene, a Phase 3 program in metastatic breast cancer. Along with our new name, our Nasdaq ticker will change to LONA, effective January 12, 2026.
We remain dedicated to advancing innovative therapies for patients with serious diseases and high unmet medical need.
Read the full announcement here: https://investors.athira.com/static-files/5a0c261e-d22b-4af9-87c7-bc15bda7315b

08/21/2024

This Friday, join us at the Alzheimer's Association, Orange County Chapter Research Advances event bringing together caregivers, patients, families, researchers, and healthcare professionals to learn about the latest in and dementia research.

Thank you to the Alzheimer’s Association for hosting this informative event to drive and educate on global research initiatives - we’re honored to be a presenting sponsor supporting this cause.

Register at no cost: https://alzassociationoc.wixstudio.io/research-advances

08/20/2024

Our Phase 2/3 LIFT-AD Study is evaluating the safety and efficacy of for the treatment of mild-to-moderate Alzheimer’s disease. Hear more on our company progress from CEO Mark Litton, Ph.D. as we approach our topline data readout of the clinical trial.

Learn more about : https://bit.ly/3zmY3Ip

08/14/2024

The mild-to-moderate stage of disease is characterized by heightened cognitive and functional decline leading to loss of patient independence. Despite this being the most distressing stage for patients and loved ones, there are currently no approved therapies to slow neurodegeneration for this specific population.

Fosgonimeton has the potential to address the mild-to-moderate stage of by providing neuroprotection and neuronal restoration, potentially reversing neurodegenerative symptoms. Stay tuned as we report topline data from our Phase 2/3 LIFT-AD clinical trial evaluating in AD in September.

Learn more: https://bit.ly/48NcRwO

08/12/2024

With multiple key data readouts expected, the space is poised for significant developments in the second half of 2024. In her recent BioSpace article, Heather McKenzie summarizes the highly anticipated neurological disease data readouts, including our LIFT-AD Phase 2/3 topline results of as a potential differentiated Alzheimer’s treatment.

Access the full article:

After a busy first half of 2024, several companies are expecting key data readouts in the neuropsychiatric and neurodegenerative disease spaces during the next six months.

08/07/2024

That’s a wrap on ! Thank you for joining our discussion of ’s neuroprotective preclinical activity in models.

See you next year!

07/25/2024

The mild-to-moderate stage of Alzheimer’s disease can be the most distressing and detrimental stage for patients, which is why disease-modifying treatments are pivotal to effectively tackle and potentially reverse neurodegeneration progression at this stage.

Hear from Dr. Anton Porsteinsson on the unmet need for new treatments to reduce patient burden below.

Listen to the full webinar on Alzheimer’s and the LIFT-AD clinical trial: https://bit.ly/3zrFW3O

07/16/2024

What’s at stake for us? Developing therapies to counteract progression of neurodegenerative diseases— our vision and mission.

President and CEO Mark Litton, Ph.D., sat down with Life Science Leader's Wayne Koberstein to highlight our approach, his experience leading the Athira team, our pipeline progress throughout the years and what’s to come.

https://bit.ly/4cO95W4

Athira Pharma is developing small molecule therapeutics for neurodegenerative diseases, including its lead candidate, fosgonimeton, for Alzheimer's disease.

07/09/2024

The last patient has completed dosing in our Phase 2/3 LIFT-AD clinical trial evaluating in mild-to-moderate disease, with topline results anticipated by end of Q3 2024.

Read the full announcement: https://investors.athira.com/news-releases/news-release-details/athira-pharma-announces-last-patient-completed-lift-ad-clinical